Sotirios Tsimikas

List of PR Articles by Year in descending order

262 PR articles	25,417 PR citations	2139 87 PR h-index	4553 153 g-index
301 documents	29358 doc citations	2336 94 h-index	20282 citing authors

#	Article	IF	PR Citations
1	Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterolâ€“Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis. Circulation, 2025, 151, 312-321.	25.2	53
2	Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests. Circulation, 2024, 149, 192-203.	25.2	45
3	Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease. Circulation, 2024, 149, 391-401.	25.2	12
4	Lipoprotein(a) levels and carotid intima-media thickness in children: A 20-year follow-up study. Journal of Clinical Lipidology, 2024, 18, e290-e294.	3.2	4
5	Updated Lipoprotein(a) Genomic Risk Score and Aspirin for Primary Prevention of Cardiovascular Events. JACC: Advances, 2024, 3, 100754.	1.4	2
6	Aspirin and Cardiovascular Risk in Individuals With Elevated Lipoprotein(a): The Multiâ€Ethnic Study of Atherosclerosis. Journal of the American Heart Association, 2024, 13, .	4.3	54
7	Increased LL37 in psoriasis and other inflammatory disorders promotes LDL uptake and atherosclerosis. Journal of Clinical Investigation, 2024, 134, .	10.7	24
8	Particle Number and Characteristics ofÂLipoprotein(a), LDL, and apoB. Journal of the American College of Cardiology, 2024, 83, 396-400.	2.4	18
9	Diacylglycerols and Lysophosphatidic Acid, Enriched on Lipoprotein(a), Contribute to Monocyte Inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2024, 44, 720-740.	6.3	40
10	Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2024, 390, 1781-1792.	43.7	178
11	Lipoprotein(a), Oxidized Phospholipids, and Progression to Symptomatic Heart Failure: The CASABLANCA Study. Journal of the American Heart Association, 2024, 13, .	4.3	15
12	In Search of an Accurate Measurement ofÂLDL-C. Journal of the American College of Cardiology, 2024, 84, 178-181.	2.4	3
13	Association of Lp(a) (Lipoprotein[a]) and Hypertension in Primary Prevention of Cardiovascular Disease: The MESA. Hypertension, 2023, 80, 352-360.	6.9	20
14	Efficacy and safety of pelacarsen in lowering Lp(a) in healthy Japanese subjects. Journal of Clinical Lipidology, 2023, 17, 181-188.	3.2	26
15	Toll-Like Receptor 3 Mediates Aortic Stenosis Through a Conserved Mechanism of Calcification. Circulation, 2023, 147, 1518-1533.	25.2	24
16	Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. Journal of Clinical Lipidology, 2023, 17, 342-355.	3.2	34
17	Blood Levels of Angiotensinogen and Hypertension in the Multi-Ethnic StudyÂofÂAtherosclerosis (MESA). Journal of the American College of Cardiology, 2023, 81, 1248-1259.	2.4	18
18	APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Journal of Clinical Lipidology, 2023, 17, 406-411.	3.2	42

#	Article	IF	PR Citations
19	High immunoglobulin-M levels to oxidation-specific epitopes are associated with lower risk of acute myocardial infarction. Journal of Lipid Research, 2023, 64, 100391.	3.7	16
20	Reducing reductionism: addressing risk for atherosclerotic cardiovascular disease by apolipoprotein proteomics. European Heart Journal, 2023, , .	2.3	3
21	Lipoprotein(a) and coronary artery calcium in comparison with other lipid biomarkers: The multi-ethnic study of atherosclerosis. Journal of Clinical Lipidology, 2023, 17, 538-548.	3.2	19
22	On-treatment platelet reactivity through the thromboxane A2 or P2Y12 platelet receptor pathways is not affected by pelacarsen. Journal of Thrombosis and Thrombolysis, 2023, , .	2.0	0
23	Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity andÂOutcomes. Journal of the American College of Cardiology, 2023, 81, 1780-1792.	2.4	75
24	Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 2023, 381, 117217.	1.6	20
25	Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. European Heart Journal, 2022, 43, 971-981.	2.3	47
26	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	2.3	174
27	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. Atherosclerosis, 2022, 341, 43-49.	1.6	36
28	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. Atherosclerosis, 2022, 349, 144-150.	1.6	24
29	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 2022, 79, 1035-1046.	2.4	182
30	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis, 2022, 346, 68-74.	1.6	13
31	Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. JCI Insight, 2022, 7, .	5.4	19
32	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. Journal of Clinical Lipidology, 2022, 16, 617-625.	3.2	41
33	Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. Atherosclerosis, 2022, 354, 15-22.	1.6	16
34	Development and validation of an isoform-independent monoclonal antibodyâ€“based ELISA for measurement of lipoprotein(a). Journal of Lipid Research, 2022, 63, 100239.	3.7	30
35	Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds. Journal of the American College of Cardiology, 2022, 80, 934-946.	2.4	103
36	Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes. Journal of the American College of Cardiology, 2022, 80, 1287-1298.	2.4	117

#	Article	IF	PR Citations
37	Assessment of efficacy and safety of volanesorsen for treatment of metabolic complications in patients with familial partial lipodystrophy: Results of the BROADEN study. Journal of Clinical Lipidology, 2022, 16, 833-849.	3.2	60
38	Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levelsâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 458-464.	6.3	68
39	A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow-Fed Young Adult Mice. Journal of Bone and Mineral Research, 2021, 36, 170-185.	5.0	14
40	Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). Journal of Clinical Lipidology, 2021, 15, 320-331.	3.2	24
41	Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. ESC Heart Failure, 2021, 8, 652-661.	3.3	80
42	Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. Journal of Lipid Research, 2021, 62, 100053.	3.7	96
43	Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Density) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2021, 41, .	6.3	40
44	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). Journal of the American College of Cardiology, 2021, 77, 1576-1589.	2.4	135
45	Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. Atherosclerosis, 2021, 324, 102-108.	1.6	25
46	Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx. JACC Basic To Translational Science, 2021, 6, 485-496.	3.4	76
47	Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. European Heart Journal, 2021, 42, 2197-2200.	2.3	18
48	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 264-275.	22.6	204
49	Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. Journal of Thrombosis and Thrombolysis, 2021, 53, 1-9.	2.0	8
50	Neutralization of oxidized phospholipids attenuates ageâ€associated bone loss in mice. Aging Cell, 2021, 20, .	7.0	30
51	Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents. Viruses, 2021, 13, 2067.	3.3	7
52	PCSK9 Activity Is Potentiated Through HDL Binding. Circulation Research, 2021, 129, 1039-1053.	12.5	18
53	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. Circulation, 2021, 144, 1940-1954.	25.2	80
54	Statins and increases in Lp(a): an inconvenient truth that needs attention. European Heart Journal, 2020, 41, 192-193.	2.3	21

#	Article	IF	PR Citations
55	Statin therapy increases lipoprotein(a) levels. European Heart Journal, 2020, 41, 2275-2284.	2.3	411
56	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Circulation, 2020, 141, 624-636.	25.2	213
57	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After AcuteÂCoronary Syndrome. Journal of the American College of Cardiology, 2020, 75, 133-144.	2.4	456
58	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. New England Journal of Medicine, 2020, 382, 244-255.	43.7	872
59	Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. Cell Metabolism, 2020, 31, 189-206.e8.	26.2	184
60	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal, 2020, 41, 4245-4255.	2.3	173
61	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). Journal of Lipid Research, 2020, 61, 1263-1270.	3.7	10
62	Lowâ€Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. Journal of the American Heart Association, 2020, 9, .	4.3	42
63	Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Current Atherosclerosis Reports, 2020, 22, .	4.9	68
64	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. European Heart Journal, 2020, 41, 3936-3945.	2.3	256
65	Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. International Journal of Cardiology, 2020, 315, 81-85.	2.3	17
66	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. Circulation Research, 2020, 126, 1346-1359.	12.5	179
67	The dedicated â€œLp(a) clinicâ€: A concept whose time has arrived?. Atherosclerosis, 2020, 300, 1-9.	1.6	79
68	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart, 2020, 106, 738-745.	4.3	39
69	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. European Heart Journal, 2020, 41, 3884-3899.	2.3	86
70	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). European Heart Journal, 2020, 41, 2262-2271.	2.3	106
71	The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia. Current Opinion in Lipidology, 2020, 31, 305-312.	4.1	13
72	microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight, 2020, 5, .	5.4	52

#	Article	IF	PR Citations
73	Reduction of myocardial ischaemiaâ€“reperfusion injury by inactivating oxidized phospholipids. Cardiovascular Research, 2019, 115, 179-189.	5.7	86
74	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. New England Journal of Medicine, 2019, 381, 531-542.	43.7	569
75	N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. European Heart Journal, 2019, 40, 2785-2796.	2.3	218
76	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. Journal of Lipid Research, 2019, 60, 1946-1952.	3.7	12
77	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. Journal of Lipid Research, 2019, 60, 2082-2089.	3.7	58
78	Diversification and CXCR4-Dependent Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM Production Linked to Human Coronary Atherosclerosis. Circulation Research, 2019, 125, .	12.5	58
79	Lipid-Lowering Agents. Circulation Research, 2019, 124, 386-404.	12.5	149
80	Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. Circulation Research, 2019, 124, 405-415.	12.5	79
81	Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement. Angiology, 2019, 70, 332-336.	2.3	14
82	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With AorticÂStenosis. Journal of the American College of Cardiology, 2019, 73, 2150-2162.	2.4	287
83	Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. CJC Open, 2019, 1, 131-140.	1.6	51
84	A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. Journal of Lipid Research, 2019, 60, 436-445.	3.7	7
85	Integrated Assessment of the Clinical Performance of GalNAc₃-Conjugated 2â€²-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. Nucleic Acid Therapeutics, 2019, 29, 16-32.	4.6	115
86	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	7.0	87
87	Relationship between â€œLDL-Câ€ estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. Journal of Clinical Lipidology, 2018, 12, 702-710.	3.2	58
88	Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, .	7.6	105
89	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a HumanÂAntibody Detects ClinicallyÂRelevant Atherothrombosis. Journal of the American College of Cardiology, 2018, 71, 321-335.	2.4	48
90	Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease. Journal of Cardiovascular Translational Research, 2018, 11, 221-229.	2.1	18

#	Article	IF	PR Citations
91	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. Journal of Clinical Lipidology, 2018, 12, 338-347.	3.2	26
92	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated RiskÂofÂCardiovascular Disease and AorticÂStenosis. Journal of the American College of Cardiology, 2018, 71, 177-192.	2.4	443
93	Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. Journal of Clinical Lipidology, 2018, 12, 122-129.e2.	3.2	52
94	The Effects of 2â€²-O-Methoxyethyl Oligonucleotides on Renal Function in Humans. Nucleic Acid Therapeutics, 2018, 28, 10-22.	4.6	68
95	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. Journal of Clinical Lipidology, 2018, 12, 1493-1501.e11.	3.2	11
96	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet, The, 2018, 392, 1311-1320.	52.8	479
97	RNA-targeted therapeutics for lipid disorders. Current Opinion in Lipidology, 2018, 29, 459-466.	4.1	58
98	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. Journal of Clinical Lipidology, 2018, 12, 1313-1323.	3.2	90
99	Oxidation-specific epitopes restrain bone formation. Nature Communications, 2018, 9, .	13.9	58
100	Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 580-588.	6.3	86
101	Oxidized Phospholipids on ApolipoproteinÂB-100 and RecurrentÂIschemic Events Following Stroke or Transient Ischemic Attack. Journal of the American College of Cardiology, 2017, 69, 147-158.	2.4	53
102	Identification of a novel series of anti-inflammatory and anti-oxidative phospholipid oxidation products containing the cyclopentenone moiety in vitro and in vivo: Implication in atherosclerosis. Journal of Biological Chemistry, 2017, 292, 5378-5391.	2.2	33
103	The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting. Angiology, 2017, 68, 795-798.	2.3	23
104	A Test in Context: Lipoprotein(a). Journal of the American College of Cardiology, 2017, 69, 692-711.	2.4	937
105	Very-Low-Density Lipoproteinâ€“Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by InhibitionÂofÂAPOC-III. Journal of the American College of Cardiology, 2017, 69, 789-800.	2.4	165
106	Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. Lancet Diabetes and Endocrinology,the, 2017, 5, 524-533.	22.6	204
107	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1206-1212.	6.3	68
108	Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1213-1221.	6.3	59

#	Article	IF	PR Citations
109	Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides. New England Journal of Medicine, 2017, 377, 222-232.	43.7	560
110	Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 1570-1578.	6.3	78
111	Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis, 2017, 260, 1-7.	1.6	8
112	Adenoviral intramyocardial VEGF-DÎ”NÎ”C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. European Heart Journal, 2017, 38, 2547-2555.	2.3	136
113	Lipoprotein(a)-Associated Molecules AreÂProminent Components in Plasma andÂValve Leaflets in Calcific Aortic ValveÂStenosis. JACC Basic To Translational Science, 2017, 2, 229-240.	3.4	73
114	Plasma Proteomics for Epidemiology. Circulation: Cardiovascular Genetics, 2017, 10, .	3.9	19
115	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3340-3348.	4.2	36
116	Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovascular Diabetology, 2017, 16, .	9.9	96
117	LPA Gene, Ethnicity, and Cardiovascular Events. Circulation, 2017, 135, 251-263.	25.2	122
118	Lipoprotein(a). Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 157-164.	2.3	56
119	Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Current Opinion in Cardiology, 2016, 31, 440-450.	1.7	71
120	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). Journal of Clinical Lipidology, 2016, 10, 594-603.	3.2	101
121	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. Journal of Clinical Lipidology, 2016, 10, 1011-1021.	3.2	122
122	Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 682-691.	6.3	102
123	Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. Journal of Thrombosis and Thrombolysis, 2016, 41, 569-580.	2.0	17
124	PCSK9 Association With Lipoprotein(a). Circulation Research, 2016, 119, 29-35.	12.5	108
125	Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease. International Journal of Angiology, 2016, 25, 044-053.	1.1	3
126	Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. Journal of Clinical Lipidology, 2016, 10, 1389-1396.	3.2	26

#	Article	IF	PR Citations
127	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation, 2016, 134, 611-624.	25.2	583
128	The re-emergence of lipoprotein(a) in a broader clinical arena. Progress in Cardiovascular Diseases, 2016, 59, 135-144.	5.9	26
129	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet, The, 2016, 388, 2239-2253.	52.8	704
130	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, .	7.6	107
131	Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2239-2245.	6.3	188
132	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. Journal of Lipid Research, 2016, 57, 697-705.	3.7	36
133	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	7.0	94
134	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. Journal of Lipid Research, 2016, 57, 706-713.	3.7	99
135	Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. Cardiovascular Drugs and Therapy, 2016, 30, 75-85.	2.1	34
136	Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. Journal of Lipid Research, 2016, 57, 340-351.	3.7	122
137	Retrieval of a detached transseptal sheath tip from a right pulmonary artery branch following catheter ablation. Catheterization and Cardiovascular Interventions, 2015, 86, 1131-1135.	1.7	3
138	â€˜LDL-Câ€™â€Š=â€ŠLDL-Câ€Š+â€ŠLp(a)-C. Current Opinion in Lipidology, 2015, 26, 169-178.	4.1	141
139	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 689-699.	6.3	187
140	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). Journal of Lipid Research, 2015, 56, 2273-2285.	3.7	106
141	Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Progressive Atherosclerosis and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 229-236.	6.3	56
142	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet, The, 2015, 386, 1472-1483.	52.8	436
143	B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. Circulation Research, 2015, 117, .	12.5	135
144	Manganese G8 dendrimers targeted to oxidationâ€specific epitopes: In vivo MR imaging of atherosclerosis. Journal of Magnetic Resonance Imaging, 2015, 41, 797-805.	3.5	28

#	Article	IF	PR Citations
145	Relationship of Oxidized Phospholipids onÂApolipoprotein B-100 to CardiovascularÂOutcomes in Patients Treated With Intensive Versus ModerateÂAtorvastatin Therapy. Journal of the American College of Cardiology, 2015, 65, 1286-1295.	2.4	70
146	Apolipoprotein C-III: From Pathophysiology to Pharmacology. Trends in Pharmacological Sciences, 2015, 36, 675-687.	11.8	171
147	Heritability of Biomarkers of Oxidized Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1704-1711.	6.3	46
148	Invasive Cardiologists Are Exposed to Greater Left Sided Cranial Radiation. JACC: Cardiovascular Interventions, 2015, 8, 1197-1206.	3.2	112
149	Oxidized Phospholipids, Lipoprotein(a),Âand Progression of CalcificÂAortic ValveÂStenosis. Journal of the American College of Cardiology, 2015, 66, 1236-1246.	2.4	376
150	Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. Journal of Lipid Research, 2015, 56, 440-448.	3.7	108
151	Prevalence of coronary artery spasm after stent placement and its association with inflammation. International Journal of Cardiology, 2015, 179, 252-255.	2.3	18
152	Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. Journal of Thrombosis and Thrombolysis, 2015, 42, 61-76.	2.0	32
153	Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis. PLoS ONE, 2014, 9, e112483.	2.4	193
154	Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions. Journal of Cardiovascular Translational Research, 2014, 7, 719-736.	2.1	19
155	What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?. Current Opinion in Lipidology, 2014, 25, 423-430.	4.1	23
156	Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans. Journal of the American College of Cardiology, 2014, 63, 1961-1971.	2.4	99
157	Highlights of the Year in JACC 2013. Journal of the American College of Cardiology, 2014, 63, 570-602.	2.4	2
158	The Severe Hypercholesterolemia Phenotype. Journal of the American College of Cardiology, 2014, 63, 1935-1947.	2.4	168
159	The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?. Diabetes, 2014, 63, 332-342.	4.4	95
160	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. Journal of the American College of Cardiology, 2014, 63, 520-527.	2.4	186
161	Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. Journal of Lipid Research, 2014, 55, 2137-2155.	3.7	51
162	Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a). Journal of the American College of Cardiology, 2014, 64, 851-860.	2.4	275

#	Article	IF	PR Citations
163	Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). Journal of the American College of Cardiology, 2014, 63, 1724-1734.	2.4	128
164	Helix-Loop-Helix Factor Inhibitor of Differentiation 3 Regulates Interleukin-5 Expression and B-1a B Cell Proliferation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2771-2779.	6.3	54
165	Secretory Phospholipase A2-IIA and Cardiovascular Disease. Journal of the American College of Cardiology, 2013, 62, 1966-1976.	2.4	122
166	Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Current Opinion in Pharmacology, 2013, 13, 168-179.	4.0	84
167	MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. Journal of Lipid Research, 2013, 54, 1877-1883.	3.7	90
168	Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis, 2013, 226, 161-164.	1.6	43
169	Highlights of the Year in JACC 2012. Journal of the American College of Cardiology, 2013, 61, 357-385.	2.4	1
170	Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease. Journal of the American College of Cardiology, 2013, 61, 2169-2179.	2.4	87
171	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). Journal of Lipid Research, 2013, 54, 2815-2830.	3.7	216
172	Oxidation-specific epitopes as targets for biotheranostic applications in humans. Current Opinion in Lipidology, 2013, 24, 426-437.	4.1	34
173	Polyoxygenated Cholesterol Ester Hydroperoxide Activates TLR4 and SYK Dependent Signaling in Macrophages. PLoS ONE, 2013, 8, e83145.	2.4	51
174	Adaptive immunity in atherogenesis: new insights and therapeutic approaches. Journal of Clinical Investigation, 2013, 123, 27-36.	10.7	182
175	Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. Journal of Lipid Research, 2012, 53, 1316-1326.	3.7	50
176	Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3058-3065.	6.3	186
177	Emerging therapeutic agents to lower lipoprotein (a) levels. Current Opinion in Lipidology, 2012, 23, 560-568.	4.1	61
178	Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. Journal of Lipid Research, 2012, 53, 2773-2790.	3.7	152
179	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. Journal of Lipid Research, 2012, 53, 1670-1678.	3.7	59
180	Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 3066-3075.	6.3	29

#	Article	IF	PR Citations
181	B-Cell Aortic Homing and Atheroprotection Depend on Id3. Circulation Research, 2012, 110, .	12.5	110
182	Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. Journal of the American College of Cardiology, 2012, 60, 2218-2229.	2.4	205
183	Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses. Cell, 2012, 151, 138-152.	34.1	563
184	Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLRâˆ'/âˆ' and ApoEâˆ'/âˆ' mice. Atherosclerosis, 2012, 222, 99-105.	1.6	42
185	In Vivo Detection of Oxidation-Specific Epitopes in Atherosclerotic Lesions Using Biocompatible Manganese Molecular Magnetic Imaging Probes. Journal of the American College of Cardiology, 2012, 59, 616-626.	2.4	62
186	Highlights of the Year in JACC 2011. Journal of the American College of Cardiology, 2012, 59, 503-537.	2.4	1
187	Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction. Journal of the American College of Cardiology, 2012, 59, 1426-1437.	2.4	75
188	Increased Expression of Oxidation-Specific Epitopes and Apoptosis Are Associated With Haptoglobin Genotype. Journal of the American College of Cardiology, 2012, 60, 112-119.	2.4	40
189	Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease. Journal of the American College of Cardiology, 2012, 60, 716-721.	2.4	212
190	Regression of Inflammation in Atherosclerosis by the LXR Agonist R211945. JACC: Cardiovascular Imaging, 2012, 5, 819-828.	7.0	73
191	Phospholipase A ‹sub›2‹/sub› Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes. Circulation, 2012, 125, 757-766.	25.2	55
192	The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. Cardiovascular Revascularization Medicine, 2012, 13, 11-19.	0.7	26
193	Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature, 2011, 478, 76-81.	38.7	516
194	Targeted Iron Oxide Particles for In Vivo Magnetic Resonance Detection of Atherosclerotic Lesions With Antibodies Directed to Oxidation-Specific Epitopes. Journal of the American College of Cardiology, 2011, 57, 337-347.	2.4	120
195	Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice. Journal of the American College of Cardiology, 2011, 57, 1611-1621.	2.4	121
196	Highlights of the Year in JACC 2010. Journal of the American College of Cardiology, 2011, 57, 480-514.	2.4	2
197	Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression. Journal of the American College of Cardiology, 2011, 58, 1715-1727.	2.4	116
198	Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. Journal of Clinical Lipidology, 2011, 5, 50-56.	3.2	15

#	Article	IF	PR Citations
199	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	3.2	245
200	Pioglitazone Modulates Vascular Inflammation in Atherosclerotic Rabbits. JACC: Cardiovascular Imaging, 2011, 4, 1100-1109.	7.0	77
201	Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. Circulation Research, 2011, 108, 235-248.	12.5	591
202	Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease. Current Pharmaceutical Design, 2011, 17, 27-37.	2.4	158
203	Successful treatment of in-stent restenosis of a covered stent graft with a paclitaxel-eluting stent. Journal of Cardiology Cases, 2011, 4, e13-e15.	0.6	1
204	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. Journal of Lipid Research, 2011, 52, 1829-1836.	3.7	125
205	Oxidized Phospholipids on apoB-100-Containing Lipoproteins: a Biomarker Predicting Cardiovascular Disease and Cardiovascular Events. Biomarkers in Medicine, 2011, 5, 673-694.	1.6	173
206	In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. Journal of Clinical Investigation, 2011, 121, 4861-4869.	10.7	88
207	Relation of Oxidative Biomarkers, Vascular Dysfunction, and Progression of Coronary Artery Calcium. American Journal of Cardiology, 2010, 105, 459-466.	1.9	60
208	Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. Journal of Lipid Research, 2010, 51, 3324-3330.	3.7	80
209	Lipoprotein(a) accelerates atherosclerosis in uremic mice. Journal of Lipid Research, 2010, 51, 2967-2975.	3.7	18
210	Oxidized Cholesteryl Esters and Phospholipids in Zebrafish Larvae Fed a High Cholesterol Diet. Journal of Biological Chemistry, 2010, 285, 32343-32351.	2.2	83
211	Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. Journal of the American College of Cardiology, 2010, 56, 946-955.	2.4	147
212	Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress. Cell Metabolism, 2010, 12, 467-482.	26.2	445
213	The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis, 2010, 209, 498-503.	1.6	38
214	Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques. Current Cardiovascular Imaging Reports, 2010, 4, 4-16.	0.6	28
215	Effects of lowâ€fat, highâ€carbohydrate diet on plasma lipoprotein(a) and oxidized phospholipids. FASEB Journal, 2010, 24, .	0.7	0
216	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Circulation, 2009, 119, 1711-1719.	25.2	140

#	Article	IF	PR Citations
217	Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency. Journal of Thrombosis and Thrombolysis, 2009, 28, 101-105.	2.0	0
218	Estrogen-Eluting Stents. Journal of Cardiovascular Translational Research, 2009, 2, 240-244.	2.1	10
219	Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial. Preventive Medicine, 2009, 49, 101-107.	2.9	139
220	Highlights of the Year in JACC 2008. Journal of the American College of Cardiology, 2009, 53, 373-398.	2.4	1
221	Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology, 2009, 53, 2186-2196.	2.4	101
222	Candidate biomarkers for the detection of coronary plaque destabilization and rupture. Current Atherosclerosis Reports, 2008, 10, 309-317.	4.9	11
223	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. Journal of the American College of Cardiology, 2008, 51, 1653-1662.	2.4	110
224	Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume. Journal of the American College of Cardiology, 2008, 52, 24-32.	2.4	97
225	Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice. Circulation, 2008, 118, 743-753.	25.2	155
226	Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. European Heart Journal, 2008, 30, 107-115.	2.3	104
227	Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. Circulation, 2008, 117, 3206-3215.	25.2	179
228	A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. Journal of Lipid Research, 2008, 49, 2230-2239.	3.7	358
229	The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Current Opinion in Lipidology, 2008, 19, 369-377.	4.1	117
230	Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1788-1795.	6.3	238
231	Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 175-181.	6.3	82
232	New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A ₂ in Atherosclerosis and Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2094-2099.	6.3	149
233	Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 850-857.	6.3	175
234	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. Journal of Lipid Research, 2007, 48, 425-433.	3.7	232

#	Article	IF	PR Citations
235	Emerging approaches for imaging vulnerable plaques in patients. Current Opinion in Biotechnology, 2007, 18, 73-82.	6.9	12
236	Measures of Oxidative Stress. Clinics in Laboratory Medicine, 2006, 26, 571-590.	1.1	45
237	C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. Journal of the American College of Cardiology, 2006, 47, C19-C31.	2.4	304
238	Imaging Vulnerable Plaque by Ultrasound. Journal of the American College of Cardiology, 2006, 47, C32-C39.	2.4	80
239	Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings. Journal of the American College of Cardiology, 2006, 47, 1803-1810.	2.4	90
240	Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease. Journal of the American College of Cardiology, 2006, 47, 2219-2228.	2.4	188
241	Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study. Journal of the American College of Cardiology, 2006, 47, 2436-2443.	2.4	67
242	Panel Discussion. Pharmacotherapy, 2006, 26, 98S-101S.	2.9	1
243	Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Current Opinion in Lipidology, 2006, 17, 502-509.	4.1	137
244	Oxidized low-density lipoprotein biomarkers in atherosclerosis. Current Atherosclerosis Reports, 2006, 8, 55-61.	4.9	81
245	Treatment of ischemic stroke complicating cardiac catheterization with systemic thrombolytic therapy. Catheterization and Cardiovascular Interventions, 2005, 66, 364-368.	1.7	10
246	Rapid progression of common femoral artery stenosis leading to development of ischemic foot ulcer following repeated ipsilateral arterial access. Catheterization and Cardiovascular Interventions, 2005, 66, 487-490.	1.7	1
247	Catheter-induced Vasospasm of Both the Right External Iliac and Right Coronary Arteries During Coronary Angiography. International Journal of Cardiovascular Imaging, 2005, 21, 481-485.	1.3	4
248	High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. Journal of Lipid Research, 2005, 46, 769-778.	3.7	54
249	Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. New England Journal of Medicine, 2005, 353, 46-57.	43.7	698
250	Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. American Heart Journal, 2005, 150, 1007-1014.	3.0	31
251	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. Circulation, 2004, 110, 1406-1412.	25.2	223
252	Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a). Circulation, 2004, 109, 3164-3170.	25.2	251

#	Article	IF	PR Citations
253	Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2307-2312.	6.3	82
254	Concomitant coronary and multiple arch vessel stenoses in patients treated with external beam radiation: Pathophysiological basis and endovascular treatment. Catheterization and Cardiovascular Interventions, 2004, 62, 385-390.	1.7	12
255	Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device. Journal of the American College of Cardiology, 2004, 43, 133-139.	2.4	36
256	Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. Journal of the American College of Cardiology, 2003, 41, 360-370.	2.4	321
257	Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a). Journal of Biological Chemistry, 2003, 278, 52841-52847.	2.2	124
258	Immunomodulatory Effects of Statins. Journal of the American Society of Nephrology: JASN, 2002, 13, 1673-1681.	0.4	114
259	Non-invasive imaging of vulnerable plaques by molecular targeting of oxidized LDL with tagged oxidation-specific antibodies. Journal of Cellular Biochemistry, 2002, 87, 138-146.	3.1	18
260	Common femoral artery anatomy is influenced by demographics and comorbidity: Implications for cardiac and peripheral invasive studies. Catheterization and Cardiovascular Interventions, 2001, 53, 289-295.	1.7	134
261	Title is missing!. Journal of Thrombosis and Thrombolysis, 2001, 11, 217-221.	2.0	3
262	Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivoâ˜†. Journal of Nuclear Cardiology, 1999, 6, 41-53.	1.5	122